^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Ilaris (canakinumab)

    i
    Associations
    News

    Trials

    Company:
    Novartis
    Drug class:
    IL-1β inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma (SPARC-1) (NCT04028245)
    Phase 1
    Columbia University
    Recruiting
    Last update posted :
    07/09/2024
    Initiation :
    08/15/2019
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    CD4
    |
    spartalizumab (PDR001) • Ilaris (canakinumab)
    Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1) (NCT03631199)
    Phase 3
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    03/20/2024
    Initiation :
    12/21/2018
    Primary completion :
    08/09/2021
    Completion :
    06/07/2027
    PD-L1
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • Ilaris (canakinumab)
    Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma (PLATforM) (NCT03484923)
    Phase 2
    Novartis Pharmaceuticals
    Completed
    Last update posted :
    01/18/2024
    Initiation :
    09/10/2018
    Primary completion :
    12/30/2022
    Completion :
    12/30/2022
    LAG3
    |
    BRAF wild-type
    |
    Kisqali (ribociclib) • Tabrecta (capmatinib) • spartalizumab (PDR001) • Ilaris (canakinumab) • ieramilimab (LAG525)
    Evaluation of Canakinumab in High-Risk Former-Smokers (NCT06038526)
    Phase 2
    Peter Shields
    Not yet recruiting
    Last update posted :
    09/14/2023
    Initiation :
    09/30/2023
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    IL1B • CASP1
    |
    Ilaris (canakinumab)
    A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (NCT02900664)
    Phase 1
    Novartis Pharmaceuticals
    Completed
    Last update posted :
    03/29/2022
    Initiation :
    08/23/2016
    Primary completion :
    03/17/2021
    Completion :
    03/17/2021
    CD8 • FOXP3
    |
    TILs
    |
    Mekinist (trametinib) • spartalizumab (PDR001) • nazartinib (EGF816) • CJM112 • Ilaris (canakinumab)